



# Æterna Zentaris

## INVESTOR FACT SHEET

**Æterna Zentaris (NASDAQ & TSX: AEZS)** is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. We are engaged in drug development activities and in the promotion of products for others. We recently received a PDUFA date from the U.S. Food & Drug Administration of December 30, 2017 for Macrilen™. The focus of our business development efforts is the in-licensing of products that are relevant to our therapeutic areas of focus in the U.S. and the out-licensing of our internally developed products for non-U.S. territories. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth from our products. For more information, visit [www.aezsinc.com](http://www.aezsinc.com).

### NEAR-TERM VALUE DRIVERS

**Macrilen™ (macimorelin)** – Oral ghrelin receptor agonist for assessing Adult Growth Hormone Deficiency (AGHD)

Æ If approved, will be the only FDA-approved drug for assessing AGHD

Æ Granted orphan drug status

Æ Patented through 2027

Æ Significant market expansion opportunity for traumatic brain injury (TBI) patients at risk of developing AGHD


Æ June 30 – Announced that we filed a New Drug Applications with the FDA for Macrilen™

Æ July 18 – Announced that the FDA granted a PDUFA date of December 30, 2017


### Proven Successful Leadership

Æ Proven leadership with record of creating shareholder value

### DEVELOPMENT PIPELINE



*Not under active development by Aeterna Zentaris*



### MILESTONES FOR 2017

#### Product Development

Macrilen™ (macimorelin) – PDUFA date of December 30, 2017

#### Business Development

Establish geographic collaborations for Macrilen™ in non-U.S. territories



### FINANCIAL DATA

Market data as of August 11, 2017	NASDAQ
Closing price per share	\$2.04
Total common shares outstanding	16.1M
Market capitalization	32.9M

<i>(in millions of US\$)</i>	As of and for the three months ended		As of and for the six months ended	
	June 30, 2017	June 30, 2016	June 30, 2017	June 30, 2016
Revenues	\$0.2	\$0.1	\$0.5	\$0.3
R&D costs	\$3.6	\$3.7	\$6.1	\$7.4
Net loss	\$(2.6)	\$(7.0)	\$(6.7)	\$(10.7)
Cash and cash equivalents <i>(no third-party debt)</i>	\$13.9	\$26.2	\$13.9	\$26.2

### STRATEGIC ALLIANCE OPPORTUNITIES

Æterna Zentaris is actively seeks strategic alliances that will facilitate the building of a product portfolio of commercial stage products in the U.S., while establishing partnerships in non-U.S. territories.

Please contact John W. Sharkey, Ph.D.  
Business Development  
[jsharkey@aezsinc.com](mailto:jsharkey@aezsinc.com)

### FOR INFORMATION OR TO RECEIVE AN INVESTOR PACKAGE:

Please contact Michael V. Ward  
[ir@aezsinc.com](mailto:ir@aezsinc.com)

Æterna Zentaris Inc.  
315 Sigma Drive, Suite 302D  
Charleston, SC 29486  
<http://www.aezsinc.com>

### FORWARD-LOOKING STATEMENT

This presentation contains forward-looking statements made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future events. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known risks and uncertainties, many of which are discussed under the caption “Key Information - Risk Factors” in our most recent Annual Report on Form 20-F filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission (“SEC”). Such statements include, but are not limited to, statements about the timing of, and prospects for, regulatory approval and commercialization of our product candidates, statements about the status of our efforts to establish a commercial operation and to obtain the right to promote or sell products that we did not develop and estimates regarding our capital requirements and our needs for, and our ability to obtain, additional financing. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in forward-looking statements. Such risks and uncertainties include, among others, our now heavy dependence on the success of Macrilen™ and the continued availability of funds and resources to successfully launch the product in the event the FDA approves Macrilen™, the rejection or non-acceptance of the NDA by one or more regulatory authorities and, more generally, uncertainties related to the regulatory process, the ability of the Company to efficiently commercialize Macrilen™, the degree of market acceptance of Macrilen™ in the event it is approved for commercialization by the FDA, our ability to take advantage of business opportunities in the pharmaceutical industry, our ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.